Chemistry:Radequinil

From HandWiki
Short description: Chemical compound
Radequinil
Radequinil.svg
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC18H14N4O3
Molar mass334.335 g·mol−1
3D model (JSmol)

Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor.[1] It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.[1][2]

See also

References

  1. 1.0 1.1 "Current Strategies of Therapy in Alzheimer's Disease". The Open Neuropsychopharmacology Journal 1: 19–23. 2008. doi:10.2174/1876523800801010019. http://benthamscience.com/open/toneuroppj/articles/V001/19TONEUROPPJ.pdf. 
  2. "List of drugs in development for neurodegenerative diseases. Update June 2007". Neuro-Degenerative Diseases 4 (6): 443–86. 2007. doi:10.1159/000107705. PMID 17934328. 

{{Navbox | name = GABA receptor modulators | title = GABA receptor modulators | state = collapsed | bodyclass = hlist | groupstyle = text-align:center;

 | group1 = Ionotropic
 |  list1 = {{Navbox|subgroup
 | groupstyle = text-align:center
 | groupwidth = 5em
   | group1 = GABAA
   | list1  = 
   | group2 = GABAA
   | list2  = 
 }}
 | group2 = Metabotropic

| list2 =

 | below = 
See also
Receptor/signaling modulators
GABAA receptor positive modulators
GABA metabolism/transport modulators

}}